Jordana Joy, Associate Editor

Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, discussed research that utilized IQVIA longitudinal prescription claims data from September through November 2023, coinciding with Miebo's FDA approval in September.

Researchers included 98 phase 2-4 uveitis trials during the time period from clinicaltrials.gov.

Steven Greenstein, MD, one of the cochairs of the Collaborative Care Symposium gave some insight into the upcoming conference and what attendees can expect.

The LMDD Eye Health Scorecard specifically evaluated insurance coverage for treatments addressing GA, neovascular AMD, and thyroid eye disease.

Catch up on the top stories in optometry during the week of May 19-May 23.

Susana Marcos, PhD, discusses the implications her research presents for the role optical coherence tomography (OCT) could play in presbyopia and myopia accommodation efforts.

The novel intraocular lens works to restore dynamic range of vision following cataract surgery.

The OTC eye drops contain low-dose brimonidine tartrate 0.025%.

The drop has the potential to become the first-ever ocular surface indication for an IG.

The cross sector initiative that intends to drive a shift from reactive to proactive health care by leveraging ocular data through the means of oculomics.

Susana Marcos, PhD, outlines a presentation she gave at ARVO 2025 on a unique utilization of optical coherence tomography.

The award marks the company's fifth consecutive recognition from the program.

DREAM is an acronym for deep imaging depth, rapid sweeping speed, extensive scan range, accurate results, and multimodal imaging capabilities.

In total, 613,690 images used for screening were included in the study.

The recent study details the diagnostic value of a multimodal model utilizing both types of biomarkers when compared with unimodal models.

The system was taught quality standards by being fed more than 1400 images from different parts of the retina taken by adaptive-optics ophthalmoscopy.

The bill, which passed on May 1, allows for West Virginian ODs to provide certain in-office procedures.

The 3200 square-foot unit offers diagnostics, cataract surgery, YAG laser capsulotomy, and post op care.

Valeda met the primary end point in the US LIGHTSIDE III trial, improving the best corrected visual acuity in patients for 24 months of >5 letters or equivalent to 1 line improvement on the eye chart, according to the company.

The drug was previously approved for high blood pressure in 1955.

Neda Shamie, MD; Selina McGee, OD, FAAO, Dipl ABO; and Jacob Lang, OD, FAAO, provided their insights during CIME 2025 on May 4.

Catch up on the top stories in optometry during the week of May 5-May 9.

The first-in-class endothelin antagonist intravitreal implant aided in increasing ocular blood flow and improved both visual function and anatomic structure, according to the company.

The Early Detection of Vision Impairments for Children Act (EDVI), or HR 2527, would allow the federal government to award grants and cooperative agreements to eligible states and communities for children's vision care initiatives.

The LuxLife full range of vision IOL is available in a range of cylinders spanning from +0.75D to +6.00D.

The recombinant human VEGFR antibody human complement receptor 1 (CR1) fusion protein will be intravitreally administered in up to 150 patients.

The trial assesses GAL-101 as an oral therapy designed to treat Alzheimer disease, dry age-related macular degeneration, and glaucoma.

After treatment cessation, eye growth returned to age-expected levels and the accumulated myopia control treatment gains were retained over the following 12 months after treatment was ceased.

Reed will be honored with the Doctor of Ocular Science honorary degree in part of the college’s 2025 commencement.

The law is the product of a 2-year collaborative effort by the North Dakota Optometric Association and the North Dakota State Board of Optometry.